Herbal remedies usually take a while to work. In Sinopharm's case, two years may be enough.
The Chinese pharmaceutical giant may revive a buyout of its 32%-owned traditional medicine arm listed in Hong Kong. A growing disconnect between the Asian hub’s markets and those on the mainland allows for the buyer to pay a bigger premium and still hope for lucrative relisting closer to home.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Breakingviews - UniCredit CEO Orcel has leverage in pay debateAndrea Orcel’s remuneration is making headlines again. The UniCredit chief executive has already had a bumper year – in January, a Madrid court awarded him 51.4 million euros in compensation after Santander withdrew a job offer. A trickier question is what the 25 billion euro Italian bank’s board should agree to pay its veteran dealmaker for his day job.
Source: Reuters - 🏆 2. / 97 Read more »
Breakingviews - The complexities of EY’s big breakup bet: podcastThe Big Four firm is pushing a plan to separate its auditing unit from its consulting business. In this Exchange podcast Andy Baldwin, global managing partner, discusses the challenges of convincing partners in over 70 countries to back the split – and what happens if it fails.
Source: Breakingviews - 🏆 470. / 51 Read more »
Breakingviews - Twitter has the most to lose against news mobMeta Platforms is taking a bold stand against a new piece of legislation, yet it’s Elon Musk’s Twitter that looks most exposed. The U.S. Congress is considering adding the “Journalism Competition and Preservation Act” to a defense bill that has a high likelihood of passing, according to Reuters. The law allows publishers to collectively negotiate with online platforms on content. The Facebook operator is threatening to pull news off its feed if it is passed, spokesperson Andy Stone tweeted. Says a loser? I do it for the LOL'S.
Source: Reuters - 🏆 2. / 97 Read more »
Breakingviews - Disney’s board needs some magicNearly all of Disney's directors were picked during Bob Iger’s first term as CEO. He’s back and part of his job is to find a replacement, something he failed to do. He needs people to challenge his thinking and prepare to exit, says jennifersaba
Source: Breakingviews - 🏆 470. / 51 Read more »
Breakingviews - Vietnam’s Tesla faces daunting Nasdaq road testElectric-car maker VinFast’s U.S. initial public offering will be a tough drive. The company, which filed its listing prospectus on Tuesday, has yet to turn a profit and only just went all-in on battery power. Its dependency on parent Vingroup may be a turnoff, too. Investors will kick the tires hard.
Source: Breakingviews - 🏆 470. / 51 Read more »
Breakingviews - Big Pharma’s heartburn win is a valuation salvePharmaceutical investors are accustomed to disappointment. An industry rule of thumb says that nine out of 10 drugs fail clinical trials, while treatments that succeed can bite companies on the tail if they have unanticipated side effects. The ghost of massive legal bill that drugmaker Bayer paid in 2020 has been haunting the sector. But a U.S. judge just made that spectre seem less threatening. Breakingviews aimeedonnellan I bet big pharma would be more careful about drugs they introduce if every time someone dies from one of their meds, one of them died as well. Breakingviews aimeedonnellan Reuters advocates for big Pharma and the clot shots.
Source: Breakingviews - 🏆 470. / 51 Read more »